This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Cefuroxime axetil
Description: Ceftin is a semisynthetic, broad-spectrum second generation cephalosporin antibiotic for oral administration. Compared to first generation cephalosporins such as Keflex, second generation cephalosporins exhibit better Gram-(-) activity and somewhat weaker Gram-(+) activity. They are more stable to Gram-(-) beta lactamases. They exhibit good activity against many enteric Gram-(-) rods, Haemophilus influenzae, and Neisseria gonorrheae; moderate activity against streptococci and staphylococci; and poor activity against enterococci, methacillin resistant Staphylococcus aureus and Psuedomonas.
As with all cephalosporins, Ceftin inhibits bacterial cell wall synthesis by inhibiting penicillin binding proteins.
Pink Sheet In Brief: Glaxo Wellcome's Ceftin
Pink Sheet Ranbaxy prevails in Ceftin lawsuit
Additional information available to subscribers only: